Trusted Resource for Clinical Trials, Protocols & Progress
In the competitive landscape of clinical trials, choosing the right sites can make or break a study. One of the most predictive indicators of future success is a site’s historical performance in prior trials. Regulators like the FDA and EMA expect sponsors and CROs to use past performance as part of risk-based site selection under ICH E6(R2) guidelines.
Click to read the full article.
Historical performance evaluation is a cornerstone of modern site feasibility processes in clinical trials. It enables sponsors and CROs to identify high-performing sites, reduce startup risks, and meet regulatory expectations. ICH E6(R2) encourages risk-based oversight, and using objective, metric-driven evaluations of previous site activity supports this mandate.
Click to read the full article.
Feasibility evaluations are often performed in silos, with site performance data stored in spreadsheets, disconnected CTMS modules, or forgotten folders. This short-term thinking results in repetitive qualification efforts, missed insights, and increased risk during site selection. A well-structured historical site database provides sponsors and CROs with a long-term, centralized repository of investigator experience, compliance trends, and enrollment metrics across multiple trials and regions.
Click to read the full article.
After a clinical trial concludes, sponsors and CROs typically conduct internal evaluations of site performance, measuring enrollment metrics, data quality, protocol adherence, and monitoring outcomes. However, many organizations fail to close the feedback loop by communicating results to the sites themselves. Professional, structured performance feedback not only helps sites improve their practices but also strengthens long-term sponsor-site relationships.
Click to read the full article.
As clinical trials grow more complex and global in scope, sponsors and CROs are increasingly turning to sites with which they have prior experience. Using repeat sites offers several advantages—faster contracting, familiarity with systems, and trusted investigators. However, re-engaging a site should never be automatic. Regulatory bodies, including the FDA and EMA, expect that site qualification be based on documented evidence of performance, including enrollment metrics, protocol adherence, and audit outcomes.
Click to read the full article.
When selecting sites for a new clinical trial, evaluating historical performance is vital—but knowing what to avoid is just as important as identifying strengths. Red flags in a site’s past trial record can signal operational weaknesses, data integrity risks, or regulatory non-compliance. Ignoring these signals may lead to delays, deviations, or even sponsor audits.
Click to read the full article.
Historically, site selection for clinical trials was often based on investigator reputation, geographic coverage, or past experience. However, as trials become increasingly complex and regulated, sponsors and CROs now seek evidence-based, data-driven site selection strategies. One of the most powerful tools for achieving this is the use of algorithms that apply weighted scores to historical performance metrics.
Click to read the full article.
In an increasingly complex regulatory and operational environment, sponsors and CROs are under pressure to select clinical trial sites that can deliver quality data, timely enrollment, and regulatory compliance. One of the most effective methods for making informed feasibility decisions is the use of historical performance metrics—quantitative and qualitative indicators drawn from a site’s previous trial involvement.
Click to read the full article.
Feasibility assessments based solely on investigator reputation or generic questionnaire responses are no longer sufficient. Regulatory expectations under ICH E6(R2) and growing emphasis on quality-by-design demand data-driven decisions—particularly when selecting or requalifying clinical trial sites. One of the most powerful tools in this regard is historical site performance data.
Click to read the full article.
Enrollment timelines are a pivotal component in determining the overall performance of clinical trial sites. A site’s ability to recruit participants on schedule not only affects trial duration and resource utilization but also signals its operational maturity, investigator engagement, and infrastructure capability. Regulatory authorities such as the FDA and EMA expect sponsors to make data-driven site selection decisions, and past enrollment performance is one of the most objective and predictive indicators available.
Click to read the full article.
